


FORM-FTO-1390 (Rev. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			003300-909
			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) unassigned 10/069006
INTERNATIONAL APPLICATION NO. PCT/SE00/01743	INTERNATIONAL FILING DATE 7 September 2000	PRIORITY DATE CLAIMED 8 September 1999 8 September 1999 8 September 1999	
TITLE OF INVENTION DEVICE FOR INTRODUCING PORES INTO BIOLOGICAL MATERIALS			
APPLICANT(S) FOR DO/EO/US SARAH FREDRIKSSON AND DARIO KRIZ			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: It is contemplated that this Application be prosecuted while using Claims 1 to 11 that were submitted on 12 October 2001 as further amended in the Preliminary Amendment filed herewith.</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or information: Certified copies of (a) Swedish Application No. 9903183-3, filed 8 September 1999, (b) Swedish Application No. 9903185-8, filed 8 September 1999, and (c) Swedish Application No. 9903187-4, filed 8 September 1999, were submitted during the international phase of prosecution. Thus the claims for priority have been perfected. 			



21839

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) unassigned 10/069006		INTERNATIONAL APPLICATION NO PCT/SE00/01743		ATTORNEY'S DOCKET NUMBER 003300-909	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,040.00 (960) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 (970) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 (958) International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 (956) International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 (962)					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 1,040.00	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	20 -20 =	0	X\$18.00 (966)	\$ -	
Independent Claims	1 -3 =	0	X\$84.00 (964)	\$ -	
Multiple dependent claim(s) (if applicable)			+\$280.00 (968)	\$ -	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,040.00	
Reduction for ½ for filing by small entity, if applicable (see below).				+ \$ 520.00	-
SUBTOTAL =				\$ 520.00	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$ -	
TOTAL NATIONAL FEE =				\$ 520.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property				+ \$ 40.00	
TOTAL FEES ENCLOSED =				\$ 560.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> Small entity status is hereby claimed. b. <input checked="" type="checkbox"/> A check in the amount of \$ <u>560.00</u> to cover the above fees is enclosed. c. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. d. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Benton S. Duffett, Jr. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620					
 SIGNATURE Benton S. Duffett, Jr. NAME				22,030 REGISTRATION NUMBER	
				February 20, 2002 DATE	

Patent
Attorney's Docket No. 003300-909

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **Box PCT**
SARAH FREDRIKSSON et al.) **Attention: DO/EO/US**
Application No.: (unassigned)) **Group Art Unit: (unassigned)**
Filed: February 20, 2002) **Examiner: (unassigned)**
For: DEVICE FOR INTRODUCING)
PORES INTO BIOLOGICAL)
MATERIALS)
)
)
)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a national phase filing of International Application No. PCT/SE00/01743,
filed September 7, 2000.

It is contemplated that this Application be prosecuted while using Claims 1 to 11
that were submitted on October 12, 2001 during the international phase of prosecution as
further amended herein.

Please amend the Application as indicated.

IN THE ABSTRACT:

Please add the Abstract of the Disclosure that is provided on a separate sheet.

IN THE CLAIMS:

Kindly replace Claims 3, 4, and 7 to 11 as follows:

3. (Amended) A method according to claim 1, wherein said magnetic field has a field strength of 1 mT.

4. (Amended) A method according to claim 1, wherein said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being generated by two coils, and said sample is inserted between the coils.

7. (Amended) A method according to claim 1, wherein said bioparticles are selected from the group comprising DNA molecules, RNA molecules, proteins, other biopolymers, peptides, chemical preparations, organic compounds, inorganic compounds or synthetic polymers or combinations thereof.

8. (Amended) A method according to claim 1, wherein said biological membrane-enveloped structures are selected from the group consisting of body tissues, cells, bacteria, virus particles, organelles at a subcellular level, liposomes or proteins.

9. (Amended) A method according to claim 1, for use for specific lysis of cells.

10. (Amended) A method according to claim 1, for use for modifying the genetic code of a host cell and/or metabolism.

11. (Amended) A device for performing the method as defined in claim 1, comprising at least one coil for generating a magnetic alternating field, optionally, a thermostat for accurate temperature control of said at least one coil, a means for variable and accurate timing control of the time during which said alternating current is on and during which a sample to be treated is exposed to said applied magnetic field, and control system for accurate setting of strength and frequency of said alternating current.

Please add the following new Claims 12 to 20:

12. (New) A method according to claim 2, wherein said magnetic field has a field strength of 1 mT.

13. (New) A method according to claim 2, wherein said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being generated by two coils, and said sample is inserted between the coils.

14. (New) A method according to claim 3, wherein said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being generated by two coils, and said sample is inserted between the coils.

15. (New) A method according to claim 12, wherein said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being generated by two coils, and said sample is inserted between the coils.

16. (New) A method according to claim 2, wherein said bioparticles are selected from the group comprising DNA molecules, RNA molecules, proteins, other biopolymers, peptides, chemical preparations, organic compounds, inorganic compounds or synthetic polymers or combinations thereof.

17. (New) A method according to claim 2, wherein said biological membrane-enveloped structures are selected from the group consisting of body tissues, cells, bacteria, virus particles, organelles at a subcellular level, liposomes or proteins.

18. (New) A method according to claim 2, for use for specific lysis of cells.

19. (New) A method according to claim 2, for use for modifying the genetic code of a host cell and/or metabolism.

20. (New) A device for performing the method as defined in claim 2, comprising at least one coil for generating a magnetic alternating field, optionally, a thermostat for accurate temperature control of said at least one coil, a means for variable and accurate timing control of the time during which said alternating current is on and during which a sample to be treated is exposed to said applied magnetic field, and control system for accurate setting of strength and frequency of said alternating current.

10059006 022002

REMARKS

The present Amendment modifies the claim format only so as to eliminate the use of multiple dependency.

An Information Disclosure Statement is being filed herewith.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Benton S. Duffett Jr.
Benton S. Duffett, Jr.
Registration No. 22,030

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: **FEBRUARY 20, 2002**

200220 "022002"

Application No. Unassigned
Attorney's Docket No. 003300-909
Page 1

Attachment to Preliminary Amendment dated February 20, 2002

Marked-up Claims - 3, 4 and 7 to 10.

3. (Amended) A method according to claim 1 [or 2], wherein said magnetic field has a field strength of 1 mT.
4. (Amended) A method according to [any one of claims 1-3] claim 1, wherein said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being generated by two coils, and said sample is inserted between the coils.
7. (Amended) A method according to [any one of claims 1-6] claim 1, wherein said bioparticles are selected from the group comprising DNA molecules, RNA molecules, proteins, other biopolymers, peptides, chemical preparations, organic compounds, inorganic compounds or synthetic polymers or combinations thereof.
8. (Amended) A method according to [any one of claims 1-7] claim 1, wherein said biological membrane-enveloped structures are selected from the group consisting of body tissues, cells, bacteria, virus particles, organelles at a subcellular level, liposomes or proteins.
9. (Amended) A method according to [any one of claims 1-8] claim 1, for use for specific lysis of cells.

10069006-022002

Attachment to Preliminary Amendment dated February 20, 2002

Marked-up Claims - 3, 4 and 7 to 10.

10. (Amended) A method according to [any one of claims 1-8] claim 1, for use for modifying the genetic code of a host cell and/or metabolism.

11. (Amended) A device for performing the method as defined in [any one of claims 1-10] claim 1, comprising at least one coil for generating a magnetic alternating field, optionally, a thermostat for accurate temperature control of said at least one coil, a means for variable and accurate timing control of the time during which said alternating current is on and during which a sample to be treated is exposed to said applied magnetic field, and control system for accurate setting of strength and frequency of said alternating current.

10069006-022002

Abstract of the Disclosure

The present invention relates to a device for creating pores in a biomaterial, such as a cell or tissue in a sample. The device uses an alternating magnetic field that increases the thermal or kinetic energy of magnetic particles present in the sample. The magnetic particles then create pores in the membrane surrounding the biostructure. Subsequently, the pores may be employed for the introduction of particles into the biostructure. In preferred embodiments the device is equipped with temperature control.

20060920 0200 1005006 90069001

DEVICE FOR INTRODUCING PORES INTO BIOLOGICAL MATERIALSField of the Invention

The present invention relates to a device for use in, inter alia, molecular biological work.

Background Art

5 In the fields of research biotechnology and biomedicine, it is often necessary to introduce a large molecule or a bioparticle into a biological structure, such as a bacterial cell. Cells and also viruses have an outer barrier for protection against the environment and
10 also a selective transport system for nutritive substances. In order to force natural protective mechanisms and introduce a substance which is not desirable for the target organism, some sort of chemical or physical treatment of the target cell is necessary. Examples of techniques of forcing the outer cell membrane of cells, and
15 where appropriate also the cell wall, are available in the fields of research genetic engineering and molecular biology.

When a new genetic code is transferred to a specially selected host cell, the technique is referred to
20 as transformation or transfection. There is no general method to be used for all types of cells, but a technique is available for each cell type and purpose. Moreover it is not possible to transform all cell types using the
25 techniques that are currently available. In 1970, Mandel and Higa (*J. Mol. Bio.* 53: 159-162) reported that *E. coli* cells which had been pre-treated with CaCl_2 could be made to take up foreign DNA when subjected to a temperature shock. After that the method has been continuously developed, (see e.g. US patent application US97/01788).
30 By exposing cells, during a fraction of a second, to an electric pulse of high voltage, pores in cell membranes open, referred to as electroporation (Zimmerman et al. *J. Membr. Biol.* 67: 165-82 (1983)), which is frequently

used as transformation technique. Bacteria, yeast and in some cases also mammalian cells and plant cells can, in specific conditions, be transformed by means of electroporation. Also in this case, a continuous development of the technique is in progress (see patent applications US97/16721, US98/16042). In the two methods described above, the cell envelope is opened sufficiently long for the DNA molecule to enter the cell. The third and last developed method for transformation is so-called lipofection (Old and Primrose, in *Principles of Gene Manipulation: An Introduction to Gene Manipulation*, Blackwell Science (1995)) where the foreign DNA is enclosed in/binds to a cationic liposome which fuses with the outer membrane of the target cell. There is one more commercial technique for transformation of plant cells, where a plant part selected for the purpose is bombarded with small gold grains which are prepared with the foreign gene (Boynton J.E. et. Science 240, 1534-1538, 1988). Such gene transfer has been developed for transformation of other tissues, such as bacteria, fungi, insect and mammalian cells (Johnston S.A. Nature 346, 776-777, 1990).

It is especially in the applications described above that the present invention can be used. However, it is quite possible to use the inventive device to introduce other exogenic materials in applications, such as direct transfer of proteins, RNA molecules, fatty acids, peptides, medical preparations etc., to study the response of specific cells and viruses. Moreover the device according to the invention is particularly suitable for lysis of cells for the purpose of carrying out lysis as well as identification and isolation of specific cellular components in one and the same method.

Summary of the Invention

Thus, the present invention relates to a device, characterised in that it comprises at least one coil in which a magnetic alternating field can be generated and

into which a sample can be inserted, where said magnetic field causes an increase of the thermal and/or kinetic energy of magnetically susceptible particles in said sample, the increased thermal and/or kinetic energy of said particles causing the formation of pores in biological membrane-enveloped structures which are to be found in said sample, said pores allowing introduction or extraction of bioparticles into/from said biological membrane-enveloped structures.

10 The method also relates to a method where a device according to the invention is used for specific lysis of cells. Furthermore the invention relates to a method where a device according to the invention is specifically used to modify the genetic code and/or metabolism of a host cell.

Brief Description of the Drawings

Fig. 1 is a principle sketch of the device according to the present invention.

Fig. 2 is an Example of an electronic current supply circuit.

Fig. 3 is an Example of the connection of a coil.

Fig. 4 shows an Example of a magnetically susceptible particle.

Fig. 5 shows a device which can generate a gradient field.

Detailed Description of the Invention

According to one aspect of the invention, the device is characterised in that said magnetic field has an alternating field direction of a frequency in the range 1-5 MHz.

According to another aspect, the device is characterised in that said magnetic field has a field strength of at least 1 mT.

According to one more aspect, the invention is characterised in that said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field being gene-

rated by two coils, and said sample is inserted between the coils.

According to one more aspect, the device according to the invention is characterised in that said coils are supplied with alternating current of different frequencies.

According to yet another aspect, the device is characterised in that said coils are supplied with either the positive or the negative part of the supplied alternating current.

According to another aspect, the device is characterised in that it is equipped with a thermostat for accurate temperature control of said coil or coils and/or said sample.

According to a further aspect, the device is characterised in that it is equipped with a variable timing for accurate control of the time during which said alternating current is on and during which said sample is exposed to said applied magnetic field.

According to another aspect, the device is characterised in that it is equipped with a control system for accurate setting of strength and frequency of said alternating current.

The biological membrane-enveloped structures consist of, inter alia, body tissue, cells, bacteria, virus particles, organelles at a sub-cellular level, liposomes or proteins.

The bioparticles that are suitable for introduction into/extraction from membrane-enveloped structures are, inter alia, DNA molecules, RNA molecules, proteins, other biopolymers, peptides, chemical preparations, organic compounds, inorganic compounds or synthetic polymers or combinations thereof.

The technique on which the invention is partly based is a combination of magnetic nanotechnology and peptide chemistry. A magnetically susceptible particle having a size of between some ten micrometers and one nanometer is

used as a reagent in the technique. When such a particle is exposed to a certain magnetic field, it is made to vibrate and generate heat. Fig. 1 is a principle sketch of the present invention. The biological sample is mixed with a reagent intended for the purpose and is then placed in a sample holder (a). The desired strength and frequency of the magnetic source (b) are adjusted, whereupon the desired temperature of the cooling element (c) is adjusted. The magnetic source is either one coil or two coils, the sample being placed between them according to Fig. 5. The magnetic source and the sample holder are enclosed in an isolated unit, in which the temperature is determined by the cooling element. To ensure the correct temperature in the sample holder, a temperature sensor (d) can be connected to the system. The variables temperature, strength and frequency of the magnetic field and treatment intervals are controlled and can be followed on a digital display (e).

Fig. 2 illustrates an example of an electronic current supply circuit which comprises an oscillator (1) based on the circuit XR2206, whose output signal (2) is amplified by a power amplifying step (3), which is based on the circuit PBD 3548/1, whose output signal (4) can operate an alternating current (1MHz, 2A) through one or more coils. An example of the connection of said coil is shown in Fig. 3, with an oscillating circuit consisting of a $2\ \Omega$ resistance (6), a $0.50\ \text{nF}$ capacitor (7) and a $50\ \mu\text{H}$ coil (8), said circuit being supplied with alternating current (5). For a person skilled in the art it is obvious that the above-described example illustrated in Figs 2 and 3 can easily be modified and that the same result can be obtained with the aid of alternative connections and coils.

Examples of magnetic materials that are used in the method according to the invention are described in the patent literature, e.g. US 4,323,056 (Borelli et al). The magnetically susceptible particle and a possible configu-

ration are also illustrated in Fig. 4. The magnetically susceptible core (9) of the particle consists essentially of magnetite (iron oxide). Further the particle is coated with an outer layer (10) consisting of a derivatised polymer (Dextran), or a monolayer or alternatively bi-layer of derivatised fatty acids. The choice of the type (number of amino acid or carbohydrate units and sequence) of ligand 11 which is used for the derivatisation is individually adapted to each application of the magnetically susceptible particle, the effect of which can be still more amplified by its surface being further modified with one or more effector molecules 12.

By adding said particles to a cell suspension and then exposing the cell to a magnetic field with alternating field direction, instantaneous heating of the medium surrounding each magnetically susceptible particle is obtained. The heat induces a temperature shock in cell and cell membrane, which causes temporary openings in the cell membrane. The heat is induced quickly and homogeneously in the entire sample, which makes it possible for the sample and the cells to be exposed to treatment for a short while, which increases the survival frequency of the exposed cells. Example 1 describes transformation of *Escherichia coli*.

In a conventional transformation method involving a temperature shock, the test tube containing the cell suspension is exposed to a higher ambient temperature (42°C), whereby a temperature gradient arises from the test tube wall and into the sample, the composition of which requires a longer time than the method according to the present invention and which further implies that the cells that are located closest to the cell wall are exposed to the higher temperature for a longer time than those in the centre of the tube. Thus, some of the cells will die owing to the increased temperature while a fraction of the cells remain untreated. The method according to the invention circumvents this problem by the instan-

taneous heating round each particle in the sample holder. The effect is amplified if the particle is besides directed immediately to the cell envelopes via the ligand molecules on the surface of the particle. This is a great
5 advantage compared with conventional transformation methods where the balance between heat shock and cells death is important to the final result.

Furthermore, the field strength of the magnetic field can be varied in space, a so-called gradient field
10 which in combination with alternating field direction causes mechanical vibrations (kinetic energy increases) in the particles, which in combination with heat radiation (thermal energy) amplifies the effect of the particles on the cell membrane surrounding all cells (and
15 cell wall, where appropriate). The present invention describes a completely new method involving induction of heat or powerful introduction of shearing forces, or a combination thereof. The shearing forces initiate dislocations in the cell membrane owing to mechanical
20 fatigue, which results in breaks in cell membranes (and cell walls in the cases where the target cell is, for example, a bacterium). The method is based on the use of an alternating externally applied gradient magnetic field. A gradient field is provided with at least two
25 coils, which are supplied with either the positive or the negative part of the supplied alternating current, or alternatively said coils are supplied with alternating current of different frequencies. A device which can generate a gradient field is described in Fig. 5. The
30 functional principle is based on two coils (A) and (B) (with or without ferrite core) being arranged opposite to each other according to Fig. 5. A control unit (C) controls the current through the coils, so that the coils only one at a time have a current passing through their
35 windings. This current alternation, whose frequency is controlled by means of the oscillator (OSC), results in the coils alternately generating the gradient magnetic

fields (D) and (E) with different gradient directions. A magnetically susceptible particle (P) located between the coils will experience a gradient magnetic field with periodically alternating direction, which will induce a mechanical vibration. Alternatively, a gradient field can be generated when the two coils are supplied with current of two different frequencies. The difference in frequency between the current in the two coils controls the frequency of the alternation of the gradient.

By letting the magnetic treatment take place for a short while, conditions are created for a large number of surviving cells after treatment. As long as the cell envelope is open, the molecule which is to be transformed should be introduced into the cell. To optimise this procedure, the molecule can also be directed to the cell envelope. Both processes are effected by connecting recognition molecules for binding on the one hand to the cell surface and, on the other hand, to said molecule of one and the same ferromagnetic particle. Molecules, which on a biochemical basis can recognise and bind to biological structures of different kinds can be, for example, short synthetic peptides, parts of an antibody or an enzyme.

By connecting a recognition molecule of a target protein, such a recombinant protein, to the magnetically susceptible particles, the device according to the invention can be used for lysis and specific purification of said target protein in one and the same method. Compared with alternative techniques of lysis (mainly enzymatic and mechanical lysis), in combination with one or more purification steps, the use of the device according to the invention saves above all time, but also material.

The inventive device can advantageously be used on the one hand for a transformation method and, on the other hand, for purification of specific cell components, which makes the device unique. Regardless of the purpose, the method should take place while the coils are kept at

a constant temperature, which means that a cooling element and a temperature control should be incorporated into the controllable magnetic equipment. Moreover it is advantageous for the various potential fields of application of the device that the strength and frequency of the magnetic field as well as the time during which the sample is exposed to the treatment are variable.

EXAMPLE 1

The following Example describes a method for transformation of *Escherichia coli* (*E.coli*) with pUC18 plasmid:

100 μ l competent *E.coli* cells are mixed at 0°C with 500 μ g pUC18 dissolved in 30 μ l 0.05 M CaCl_2 . The sample is introduced into the sample container in the device according to the invention and incubated for 30 min at 0°C in the coil. Then the sample is treated for 30 s at 1MHz, 2A. 1 ml sterile LB broth is then added to the sample, which is then incubated in water bath for 1 h at 37°C. Subsequently the cells are spread on agar plates containing selection pressure, 50 μ g/ μ l ampicillin, for only the transformed bacteria to be obtained. The experiment should include a reference sample which does not contain pUC18 in order to assess survival and transformation frequency.

CLAIMS

1. A device, characterised in that it
5 comprises at least one coil, in which a magnetic alternating field can be generated and into which a sample can be inserted, where said magnetic field causes an increase of the thermal and/or kinetic energy of magnetically susceptible particles in said sample, the increased thermal
10 and/or kinetic energy of said particles causing the formation of pores in biological membrane-enveloped structures which are to be found in said sample, said pores allowing introduction or extraction of bioparticles into/from said biological membrane-enveloped structures.

15 2. A device as claimed in claim 1, characterised in that said magnetic field has an alternating field direction of a frequency in the range 1-5 MHz.

20 3. A device as claimed in claim 1 or 2, characterised in that said magnetic field has a field strength of at least 1 mT.

4. A device as claimed in any one of claims 1-3, characterised in that said magnetic field is non-homogeneous and has an alternating gradient field direction, the direction of said alternating gradient field
25 being generated by two coils, and said sample is inserted between the coils.

5. A device as claimed in claim 4, characterised in that said coils are supplied with alternating current of different frequencies.
30

6. A device as claimed in claim 4, characterised in that said coils are supplied with either the positive or the negative part of the supplied alternating current.

7. A device as claimed in any one of claims 1-6, characterised in that it is equipped with a thermostat for accurate temperature control of said coil or coils and/or said sample.

5 8. A device as claimed in any one of claims 1-7, characterised in that it is equipped with a variable timing for accurate control of the time during which said alternating current is on and during which said sample is exposed to said applied magnetic field.

10 9. A device as claimed in any one of claims 1-8, characterised in that it is equipped with a control system for accurate setting of strength and frequency of said alternating current.

15 10. A device as claimed in any one of claims 1-9, characterised in that said biological membrane-enveloped structures consist of body tissue, cells, bacteria, virus particles, organelles at a sub-cellular level, liposomes or proteins.

20 11. A device as claimed in any one of claims 1-10, characterised in that said bioparticles are DNA molecules, RNA molecules, proteins, other biopolymers, peptides, chemical preparations, organic compounds, inorganic compounds or synthetic polymers or combinations thereof.

25 12. A method in which the device as claimed in any one of claims 1-10 is used for specific lysis of cells.

13. A method in which the device as claimed in any one of claims 1-10 is specifically used to modify the genetic code of a host cell and/or metabolism.

1/5

FIG. 1.




FIG. 2




FIG. 3






FIG. 4.



5/5

FIG. 5.



COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to Provisional and International (PCT) Applications)

Attorney's Docket
No. 003300-909

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (IF ONLY ONE NAME IS LISTED BELOW) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (IF PLURAL NAMES ARE LISTED BELOW) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

DEVICE FOR INTRODUCING PORES INTO BIOLOGICAL MATERIALS

The specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States Patent Application Number _____
on _____
and was amended on _____ (if applicable).
- ☐ was filed as International (PCT) Application Number _____
on _____
and was amended on _____ (if applicable).

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE U.S. PATENT AND TRADEMARK OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any International (PCT) Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International (PCT) Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119
Sweden	9903183-3	8 September 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Sweden	9903185-8	8 September 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Sweden	9903187-4	8 September 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

(APPLICATION NUMBER)

(FILING DATE)

(APPLICATION NUMBER)

(FILING DATE)

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)
(Includes Reference to Provisional and International (PCT) Applications)

Attorney's Docket
No. 003300-909

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or International (PCT) Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations § 1.56, which became available between the filing date of the prior application(s) and the national or international filing date of this application:

PRIOR U.S. APPLICATIONS OR INTERNATIONAL (PCT) APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:

U.S. APPLICATIONS		STATUS (check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)		
SE00/01743	7 September 2000			

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the U.S. Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Weisblatt	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,885	Harold R. Brown III	36,341
Norman H. Stepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudziecki	24,970	T. Gene Dillahunt	25,423	Steven M. duBois	35,023
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858	Brian P. O'Shaughnessy	32,747
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344	Kenneth B. Leffler	36,075
Regis E. Slutter	26,999	William H. Benz	25,952	Fred W. Hathaway	32,236
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Wendi L. Weinstein	34,456
Robert G. Mukai	28,531	Richard J. McGrath	29,195	Mary Ann Dillahunt	34,576
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814		
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		



21839

and: _____

Address all correspondence to:

BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria, Virginia 22313-1404



21839

Address all telephone calls to: _____ at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D)
(Includes Reference to Provisional and International (PCT) Applications)

Attorney's Docket
No. 003300-909

FULL NAME OF SOLE OR FIRST INVENTOR Sarah FREDRIKSSON		SIGNATURE <i>Sarah Fredriksson</i>	DATE 13 February 2002
RESIDENCE (CITY & STATE/COUNTRY) Staffanstorps, Sweden		CITIZENSHIP Swedish	
POST OFFICE ADDRESS (HOME ADDRESS) Möllarevägen 1, 245 61 STAFFANSTORP, SWEDEN			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY Dario KRIZ		SIGNATURE <i>Dario Kriz</i>	DATE 13 February 2002
RESIDENCE (CITY & STATE/COUNTRY) Höör, Sweden		CITIZENSHIP Swedish	
POST OFFICE ADDRESS (HOME ADDRESS) Bosjökloster Bonhuset, 243 95 HÖÖR, SWEDEN			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF NINTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			
FULL NAME OF TENTH JOINT INVENTOR, IF ANY		SIGNATURE	DATE
RESIDENCE (CITY & STATE/COUNTRY)		CITIZENSHIP	
POST OFFICE ADDRESS (HOME ADDRESS)			